Biogen adds patent for multiple sclerosis drug Tecfidera

03/20/2013 | Reuters

Biogen Idec obtained a new patent for its multiple sclerosis drug Tecfidera, which could receive FDA approval this month. The patent on a daily dosing regimen of 480 milligrams is due to expire in 2028.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC